How does KTTA's PB Ratio compare to its peers?

KTTA is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (1x).

How does KTTA's PB Ratio compare vs other companies in the US Biotechs Industry?

KTTA is good value based on its Price-To-Book Ratio (0.2x) compared to the US Biotechs industry average (1.8x).

What is KTTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate KTTA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of KTTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate KTTA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Pasithea Therapeutics (Nasdaq:KTTA) - Stock Price, News & Analysis

KTTA Stock Overview

A biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. More details

KTTA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($4M)

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Earnings have declined by 53.8% per year over past 5 years

+ 2 more risks

Pasithea Therapeutics Corp. Competitors

Aptinyx

OTCPK:APTX

US$6.5m

Cyclerion Therapeutics

NasdaqCM:CYCN

US$3.6m

Aptevo Therapeutics

NasdaqCM:APVO

US$4.9m

Enzon Pharmaceuticals

OTCPK:ENZN

US$5.3m

Price History & Performance

Summary of all time highs, changes and price drops for Pasithea Therapeutics
Historical stock prices
Current Share Price	US$3.10
52 Week High	US$17.40
52 Week Low	US$2.92
Beta	0.82
11 Month Change	-23.27%
3 Month Change	-33.33%
1 Year Change	-49.90%
33 Year Change	-96.13%
5 Year Change	n/a
Change since IPO	-95.65%

Recent updates

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Jul 21

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Apr 06

Shareholder Returns

	KTTA	US Biotechs	US Market
7D	-8.3%	-3.7%	0.3%
1Y	-49.9%	15.2%	31.1%

Return vs Industry: KTTA underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: KTTA underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is KTTA's price volatile compared to industry and market?
KTTA volatility
KTTA Average Weekly Movement	21.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KTTA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KTTA's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2020	8	Tiago Marques	www.pasithea.com

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.

Pasithea Therapeutics Corp. Fundamentals Summary

How do Pasithea Therapeutics's earnings and revenue compare to its market cap?
KTTA fundamental statistics
Market cap	US$3.93m
Earnings (TTM)	-US$15.76m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is KTTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KTTA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.76m
Earnings	-US$15.76m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-12.44
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did KTTA perform over the long term?

See historical performance and comparison

KTTA Stock Overview

Risk Analysis

Pasithea Therapeutics Corp. Competitors

OTCPK:APTX

US$6.5m

NasdaqCM:CYCN

US$3.6m

NasdaqCM:APVO

US$4.9m

OTCPK:ENZN

US$5.3m

Price History & Performance

Recent News & Updates

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

New major risk - Financial position

Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

New minor risk - Share price stability

Recent updates

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

New major risk - Financial position

Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

New minor risk - Share price stability

Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients

New major risk - Financial position

Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate

Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023

High number of new and inexperienced directors

Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.

New major risk - Share price stability

Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.

Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics

Price target decreased to US$2.30

Less than half of directors are independent

Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp

Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics

Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.

Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp

Less than half of directors are independent

Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors

Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board

Camac Partners Provides Information to Shareholders of Pasithea Therapeutics

Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis

Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting

Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp

We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate

Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away

Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation

Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding

Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding

Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K

Shareholder Returns

Price Volatility

About the Company

Pasithea Therapeutics Corp. Fundamentals Summary

0.0x

-0.2x

Earnings & Revenue